<p>2025 年 9 月 30 日，ESSA Pharma Inc.（納斯達克代碼：EPIX）公佈了關於其與 XenoTherapeutics Inc.的商業合併協議的重要更新。兩者之間的合作預計將帶來變革性的變化，南舊金山和温哥華將成為這些發展的重要中心。這一舉措標誌着 ESSA 向前邁出了關鍵一步，展示了其在生物科技領域對合作與創新的承諾。這一戰略合併將產生廣泛的影響，體現了行業向有影響力、以使命為驅動的事業不斷演變的趨勢。</p>

ESSA銀行

<p>ESSA Pharma Inc.（納斯達克代碼：EPIX）已就其與 XenoTherapeutics Inc.的業務合併協議提供了最新進展。此次合作旨在推動生物技術領域的變革，以南舊金山和温哥華為關鍵中心。這一戰略性合併突顯了 ESSA 對創新和合作的承諾，標誌着行業向有影響力的、以使命為驅動的倡議的重要演變</p>

<p>On September 30, 2025, ESSA Pharma Inc. (NASDAQ: EPIX) revealed a significant update regarding its Business Combination Agreement with XenoTherapeutics Inc. The collaboration between the two entities is expected to bring about transformative changes, with South San Francisco and Vancouver serving as significant hubs for these developments. This initiative marks a crucial step forward for ESSA, showcasing its commitment to partnerships and innovation in the biotech sector. The strategic merger is set to have wide-reaching implications, exemplifying the ongoing evolution of the industry towards impactful, mission-driven endeavors.</p>
<div class="lb-trans"><p>2025 年 9 月 30 日，ESSA Pharma Inc.（納斯達克代碼：EPIX）公佈了關於其與 XenoTherapeutics Inc.的商業合併協議的重要更新。兩者之間的合作預計將帶來變革性的變化，南舊金山和温哥華將成為這些發展的重要中心。這一舉措標誌着 ESSA 向前邁出了關鍵一步，展示了其在生物科技領域對合作與創新的承諾。這一戰略合併將產生廣泛的影響，體現了行業向有影響力、以使命為驅動的事業不斷演變的趨勢。</p>
</div>

ESSA Pharma provides update on Supreme Court application for amended interim order regarding its Business Combination Agreement with XenoTherapeutics Inc. (NASDAQ: EPIX)

ESSA Pharma 就其與 XenoTherapeutics Inc. (NASDAQ: EPIX) 的業務合併協議修訂臨時命令的最高法院申請提供了最新信息